Which is best to invest in: Bionano genomics, Intellia, or Editas?

In the world of science, there is always something new on the horizon. While some discoveries and technologies make a more significant impact than others, it can be hard to determine which avenue of research is best to invest in. In the race to develop new genomic technologies, there are three clear front runners: Bionano Genomics, Intellia, and Editas. So, which should you invest in?

To start with, let’s examine what each of these companies does. Bionano Genomics develops and commercializes high-resolution gene-sequencing technology. Intellia Therapeutics uses CRISPR gene-editing technology to develop treatments for rare diseases. And Editas Medicine is focused on developing novel, genome-editing medicines for patients with serious diseases.

Bionano’s technology is based on aNob, a protein that binds single strands of DNA. This technology is different from traditional DNA sequencing methods, which can only measure the amount of DNA present. Bionano’s technology can measure the location of each DNA strand and the sequence of bases on that strand. This level of detail is important for researchers and clinicians because it allows them to see how genes interact with each other and how they are regulated.

Intellia Therapeutics is using CRISPR gene-editing technology to develop treatments for rare diseases. CRISPR, or clustered regularly interspaced short palindromic repeats, is a naturally occurring DNA sequence that confers immunity to bacteria. CRISPR technology uses this sequence to target and edit specific genes. Intellia has developed a CRISPR platform that can be used to target any gene.

Editas Medicine is also using CRISPR gene-editing technology to develop novel, genome-editing medicines for patients with serious diseases. Editas’s CRISPR platform uses a modified CRISPR protein called Cpf1. Unlike the CRISPR protein used by Intellia and Editas, the Cpf1 protein can bind to DNA strands that are not perfectly complementary. This means that Cpf1 can be used to edit genes that are not currently accessible to the CRISPR protein.

Bionano, Intellia, and Editas are all developing exciting new technologies, but which one is the best investment?

Conclusion

It is difficult to make a definitive decision on which company to invest in when it comes to Bionano genomics, Intellia, and Editas. All three companies have the potential to be great investments, but it is important to do your own research before investing in any of them.